Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26494313 | 1.00 | ACHE (0.34) | ACHEOPRK1 | |
| SCHEMBL26494315 | 1.00 | ACHE (0.34) | ACHEOPRK1 | |
| SCHEMBL26494337 | 0.98 | ACHE (0.33) | ACHEOPRK1 | |
| SCHEMBL26494096 | 0.98 | ACHE (0.33) | ACHEOPRK1 | |
| SCHEMBL26494341 | 0.98 | ACHE (0.33) | ACHEOPRK1 | |
| SCHEMBL25075128 | 0.92 | TLR9 (0.35) | ACHEOPRK1 | |
| SCHEMBL26496238 | 0.92 | TLR9 (0.35) | ACHEOPRK1 | |
| SCHEMBL25075312 | 0.92 | TLR9 (0.35) | ACHEOPRK1 | |
| SCHEMBL26494324 | 0.92 | TLR9 (0.35) | ACHEOPRK1 | |
| SCHEMBL26496240 | 0.92 | TLR9 (0.35) | ACHEOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | ACHE 3459/4885OPRK1 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.